Literature DB >> 8576585

Use of immobilized adenosine deaminase (EC 3.5.4.4) for the rapid purification of native human CD26/dipeptidyl peptidase IV (EC 3.4.14.5).

I de Meester1, G Vanhoof, A M Lambeir, S Scharpé.   

Abstract

The leukocyte differentiation antigen CD26 identified as dipeptidyl peptidase IV.(EC 3.4.14.5), cleaves off N-terminal dipeptides from peptides when a proline or alanine is located at the penultimate position. Seminal plasma and especially prostasomes, prostate-derived organelles which occur freely in seminal plasma, contain high amounts of CD26/dipeptidyl peptidase IV and therefore are suitable sources for the purification of the protein. The use of adenosine deaminase (EC 3.5.4.4) affinity chromatography for its purification is described. CD26/dipeptidyl peptidase IV was purified from human seminal plasma and prostasomes by a two step procedure. Ion exchange chromatography on DEAE-Sepharose, followed by affinity chromatography on adenosine deaminase-Sepharose resulted in the pure, native protein with an overall yield ranging from 35 to 55%. The N-terminal sequence of the amphiphilic enzyme purified from human prostasomes was determined to be Met-Lys-Thr-Pro-Trp-Lys-Val-Leu. The preparation obtained was free of contaminating aminopeptidase activity and proved to be very stable (up to 1 month at 37 degrees C). The calf intestinal adenosine deaminase we used is commercially available and can be employed for the purification of human, bovine and rabbit CD26/dipeptidyl peptidase IV. High affinity binding of porcine dipeptidyl peptidase IV was not observed. The availability of a source with high specific activity and the introduction of adenosine deaminase affinity chromatography permits the rapid purification of milligram quantities of natural mammalian CD26/dipeptidyl peptidase IV.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8576585     DOI: 10.1016/0022-1759(95)00239-1

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  13 in total

1.  Enzymatic properties of dipeptidyl aminopeptidase IV produced by the periodontal pathogen Porphyromonas gingivalis and its participation in virulence.

Authors:  Y Kumagai; K Konishi; T Gomi; H Yagishita; A Yajima; M Yoshikawa
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

2.  Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis.

Authors:  Zubair Shah; Thomas Kampfrath; Jeffrey A Deiuliis; Jixin Zhong; Colleen Pineda; Zhekang Ying; Xiaohua Xu; Bo Lu; Susan Moffatt-Bruce; Rekha Durairaj; Qinghua Sun; Georgeta Mihai; Andrei Maiseyeu; Sanjay Rajagopalan
Journal:  Circulation       Date:  2011-10-17       Impact factor: 29.690

3.  Streptokinase promotes development of dipeptidyl peptidase IV (CD26) autoantibodies after fibrinolytic therapy in myocardial infarction patients.

Authors:  Miguel Cuchacovich; Héctor Gatica; Paula Vial; Jorge Yovanovich; Salvatore V Pizzo; Mario Gonzalez-Gronow
Journal:  Clin Diagn Lab Immunol       Date:  2002-11

4.  Fibroblast Activation Protein (FAP) targeting homodimeric FAP inhibitor radiotheranostics: a step to improve tumor uptake and retention time.

Authors:  Euy Sung Moon; Sanjana Ballal; Madhav Prasad Yadav; Chandrasekhar Bal; Yentl Van Rymenant; Sarah Stephan; An Bracke; Pieter Van der Veken; Ingrid De Meester; Frank Roesch
Journal:  Am J Nucl Med Mol Imaging       Date:  2021-12-15

5.  Kinetic investigation of human dipeptidyl peptidase II (DPPII)-mediated hydrolysis of dipeptide derivatives and its identification as quiescent cell proline dipeptidase (QPP)/dipeptidyl peptidase 7 (DPP7).

Authors:  Marie-Berthe Maes; Anne-Marie Lambeir; Kambiz Gilany; Kristel Senten; Pieter Van der Veken; Barbara Leiting; Koen Augustyns; Simon Scharpé; Ingrid De Meester
Journal:  Biochem J       Date:  2005-03-01       Impact factor: 3.857

6.  Enzyme activity and immunohistochemical localization of dipeptidyl peptidase 8 and 9 in male reproductive tissues.

Authors:  Véronique Dubois; Chris Van Ginneken; Hilde De Cock; Anne-Marie Lambeir; Pieter Van der Veken; Koen Augustyns; Xin Chen; Simon Scharpé; Ingrid De Meester
Journal:  J Histochem Cytochem       Date:  2009-02-02       Impact factor: 2.479

7.  The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism.

Authors:  Michael Engel; Torsten Hoffmann; Leona Wagner; Michael Wermann; Ulrich Heiser; Reiner Kiefersauer; Robert Huber; Wolfram Bode; Hans-Ulrich Demuth; Hans Brandstetter
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-10       Impact factor: 11.205

8.  The binding site of human adenosine deaminase for CD26/Dipeptidyl peptidase IV: the Arg142Gln mutation impairs binding to cd26 but does not cause immune deficiency.

Authors:  E Richard; F X Arredondo-Vega; I Santisteban; S J Kelly; D D Patel; M S Hershfield
Journal:  J Exp Med       Date:  2000-11-06       Impact factor: 14.307

9.  In Vitro Evaluation of the Squaramide-Conjugated Fibroblast Activation Protein Inhibitor-Based Agents AAZTA5.SA.FAPi and DOTA.SA.FAPi.

Authors:  Euy Sung Moon; Yentl Van Rymenant; Sandeep Battan; Joni De Loose; An Bracke; Pieter Van der Veken; Ingrid De Meester; Frank Rösch
Journal:  Molecules       Date:  2021-06-08       Impact factor: 4.411

10.  Circulating Stromal Cell-Derived Factor 1α Levels in Heart Failure: A Matter of Proper Sampling.

Authors:  Lesley Baerts; Yannick Waumans; Inger Brandt; Wolfgang Jungraithmayr; Pieter Van der Veken; Marc Vanderheyden; Ingrid De Meester
Journal:  PLoS One       Date:  2015-11-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.